Home
Service
Small Molecule Services
Macromolecular Services
In vitro ADME Screening Services
Animal Experimental Services
Daily Chemical Testing Service
Our Clients
COOPERATION CUSTOMERS
Apply immediately
Articles
Article published
Academic research
Guarantee
Quality Assurance
Organizational guarantee
Process assurance
Information Assurance
Technical support
News
Guochen Dynamic
Industry News
About Us
Company Profile
Enterprise culture
Development process
Contact Us
This local medical device company's profit in the first quarter exceeded 3.1 billion! Mindray, Xinhua, and United Imaging ranked in the top three, while GE, Philips, and Siemens lost momentum
Recently, the first quarter reports of major domestic medical device companies have all been released. The New Media Center of "Pharmaceutical Economic News" has comprehensively sorted out the financial report data of the top 5 medical device companies. Among them, Mindray Medical, Xinhua Medical, United Imaging Healthcare, Yuyue Medical, and Intech Medical have revenues exceeding 2 billion yuan; if ranked by R&D investment, Mindray Medical, United Imaging Healthcare, Neusoft Medical, Lepu Medical, and Yuyue Medical rank high, and their R&D investment has exceeded 100 million yuan.
25
2024
/
05
General considerations for ADC clinical dose optimization
In recent years, dose optimization has become a key focus of the FDA when reviewing new oncology drugs.
24
$9 billion! Eli Lilly invests to expand telportipad production capacity
On May 24, Eli Lilly announced that its investment in its Lebanon, Indiana manufacturing site has more than doubled, with a new investment of $5.3 billion, bringing the company's total investment in the manufacturing site from $3.7 billion to $9 billion. The expansion will increase Eli Lilly's ability to produce tirpotide, Zepbound injection, and Mounjaro injection active pharmaceutical ingredients (API), so that more patients with chronic diseases such as obesity and type 2 diabetes can benefit from it.
China's King of Medicine vs. World's King of Medicine "Sales TOP List"
The world's leading drug in 2023 is Merck's oncology antibody therapy Keytruda, with annual sales reaching US$25 billion, a year-on-year increase of nearly 20%.
Leading the nuclear medicine track, opening the road of RLT commitment to China
On April 22, the 2024 Radiopharmaceutical Innovation and Development Conference hosted by the China Isotope and Radiation Industry Association was held in Beijing.
28
04
Baili Tianheng's R&D investment in 2023 will increase by 99% year-on-year
On April 26, Baili Tianheng announced its 2023 performance, achieving operating income of RMB 562 million, a decrease of 20.11% from the same period last year. Net profit attributable to the listed company was RMB -780 million, a year-on-year decrease of 176.40%. The main reason was that during the reporting period, the Phase III clinical trial was carried out, and preclinical research and clinical trial research continued to be invested. With the continuous advancement of R&D progress, R&D investment increased, resulting in the company's R&D expenses continuing to grow.
27
